TY - JOUR
T1 - Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model
T2 - Model development and evaluation and derivation of analytical solutions for ka and Fa
AU - Usansky, Helen H.
AU - Sinko, Patrick J.
PY - 2005/7
Y1 - 2005/7
N2 - Intestinal transcellular permeability (Pm), measured across cell lines such as Caco-2 cells in vitro, is often used for assessing oral drug absorption potential in humans. However, the quantitative link between in vitro permeability and apparent in vivo absorption kinetics, based on drug appearance in plasma, is poorly understood. In the current study, a novel absorption-disposition kinetic model that links traditional pharmacokinetic and mass transfer models was developed. Analytical solutions of ka and Fa were deduced, and using Caco-2 permeability, Fa in humans was predicted for 51 structurally diverse compounds. Predicted F a values were similar to and correlated highly with their corresponding experimental values with an average error of 1.88 ± 1.06% (-17 to 22%) and r2 = 0.934. Simulated concentration profiles for 17 of 18 drugs corresponded to observed plasma concentration profiles in healthy volunteers. The equilibrium solution for ka (ka,eq) was found to be a key determinant of Fa, whereas under sink conditions, ka is likely to be a determinant of plasma concentration kinetics. The current version of the model offers a quantitative approach for predicting human oral absorption kinetics from in vitro permeability. It also establishes, for the first time, a quantitative link between Pm and ka and between ka,eq and Fa. This will facilitate better in vitro or in situ-in vivo correlations since it establishes a basis for incorporating permeability coefficients from the various experimental formats based on drug loss or appearance that are commonly used in the laboratory for permeability determination.
AB - Intestinal transcellular permeability (Pm), measured across cell lines such as Caco-2 cells in vitro, is often used for assessing oral drug absorption potential in humans. However, the quantitative link between in vitro permeability and apparent in vivo absorption kinetics, based on drug appearance in plasma, is poorly understood. In the current study, a novel absorption-disposition kinetic model that links traditional pharmacokinetic and mass transfer models was developed. Analytical solutions of ka and Fa were deduced, and using Caco-2 permeability, Fa in humans was predicted for 51 structurally diverse compounds. Predicted F a values were similar to and correlated highly with their corresponding experimental values with an average error of 1.88 ± 1.06% (-17 to 22%) and r2 = 0.934. Simulated concentration profiles for 17 of 18 drugs corresponded to observed plasma concentration profiles in healthy volunteers. The equilibrium solution for ka (ka,eq) was found to be a key determinant of Fa, whereas under sink conditions, ka is likely to be a determinant of plasma concentration kinetics. The current version of the model offers a quantitative approach for predicting human oral absorption kinetics from in vitro permeability. It also establishes, for the first time, a quantitative link between Pm and ka and between ka,eq and Fa. This will facilitate better in vitro or in situ-in vivo correlations since it establishes a basis for incorporating permeability coefficients from the various experimental formats based on drug loss or appearance that are commonly used in the laboratory for permeability determination.
UR - http://www.scopus.com/inward/record.url?scp=23044469809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23044469809&partnerID=8YFLogxK
U2 - 10.1124/jpet.104.076182
DO - 10.1124/jpet.104.076182
M3 - Article
C2 - 15833900
AN - SCOPUS:23044469809
SN - 0022-3565
VL - 314
SP - 391
EP - 399
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 1
ER -